Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Advixa
- Development stage
- Phase 3
- Lead developer
- Incepta Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Advixa is a biosimilar monoclonal antibody to adalimumab (Humira), developed and manufactured by Incepta Pharmaceuticals in Bangladesh. It is a recombinant human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor-alpha (TNF-alpha), blocking its interaction with the p55 and p75 cell surface TNF receptors. This inhibition neutralizes the biological activity of TNF-alpha, a key pro-inflammatory cytokine involved in the pathogenesis of various autoimmune diseases. Advixa is primarily indicated for the treatment of moderate to severe rheumatoid arthritis, where it has demonstrated non-inferiority to the reference product in clinical trials conducted in collaboration with the Institute for Developing Science and Health Initiatives (ideSHi). It is also used for other inflammatory conditions such as psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
- Brand names
- Advixa
- Other names
- adalimumab biosimilarIncepta adalimumab
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Advixa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Advixa.